Celator Pharmaceuticals, Inc. Raises $39.3 Million
5/1/2013 8:27:03 AM
More...
|
Celator Pharmaceuticals, Inc. Announces Data on the Effects of CPX-351 in High Risk AML Presented at the American Society of Hematology Annual Meeting
12/11/2012 10:42:47 AM
More...
|
The Leukemia & Lymphoma Society and Celator Pharmaceuticals, Inc. Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
7/5/2012 10:00:24 AM
More...
|
Celator Pharmaceuticals, Inc. Announces Presentations of Positive Survival Analyses from CPX-351 Studies at American Society of Clinical Oncology Annual Meeting
6/5/2012 10:40:07 AM
More...
|
Celator Pharmaceuticals, Inc. Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia
1/26/2012 7:20:16 AM
More...
|
Celator Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society Announce Positive Data from Phase 2b Study of CPX-351 at the American Society of Hematology Annual Meeting
12/12/2011 8:21:42 AM
More...
|
Celator Pharmaceuticals, Inc. Granted U.S. Patent Covering Lead Cancer Product
9/21/2011 10:46:35 AM
More...
|
Celator Pharmaceuticals, Inc. Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Clinical Oncology Meeting
6/6/2011 11:27:05 AM
More...
|
Celator Pharmaceuticals, Inc. and Cephalon, Inc. (CEPH) Agree to Extend Research Agreement into Next Phase of Development
1/10/2011 9:13:10 AM
More...
|
Celator Pharmaceuticals, Inc. Issued U.S. Patent Related to CombiPlex(R) Technology Platform
12/16/2010 9:10:53 AM
More...
|
|